Consensus on amantadine use in influenza A

Elliott, Josephine

doi:10.1001/jama.242.22.2383

Cited by 7 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Studies performed over the past 15 years have confirmed the therapeutic benefit of amantadine when given early in the course of acute illness due to influenza A virus, both in shortening the duration of symptoms and in decreasing their severity (6,10). Despite these reports, amantadine is not widely used by medical practitioners.…”

mentioning

confidence: 97%

Reduction in fever and symptoms in young adults with influenza A/Brazil/78 H1N1 infection after treatment with aspirin or amantadine

Younkin¹,

Betts²,

Roth³

et al. 1983

Antimicrob Agents Chemother

105

View full text Add to dashboard Cite

During an outbreak of influenza A/Brazil/78 H1N1 infection, 47 volunteers with clinical and virological influenza of less than 2 days duration were treated in a randomized double-blind fashion for 5 days with 100 or 200 mg of amantadine daily or with 3.25 g of aspirin daily. The aspirin treatment group defervesced more rapidly (10.3 h versus 21.5 h and 23.6 h; P less than 0.01), but by the second daily follow-up visit, both groups of amantadine recipients exhibited greater symptomatic improvement. Bothersome side effects resulted in discontinuation of therapy by 35% of the aspirin treatment group but only 3% of the amantadine treatment group (P less than 0.05). Individuals who present to a physician during an influenza A epidemic with characteristic symptoms will experience symptomatic benefit from amantadine treatment, with negligible toxicity.

show abstract